‒ Significant Reduction in Death Observed in Patients Who Received Immunotherapy and Commonly Prescribed Oral Treatments, Regardless of Treatment Order ‒
San Francisco, CA (UroToday.com) — Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced the publication of an analysis examining real-world survival outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with PROVENGE®(sipuleucel-T) and commonly prescribed oral treatments.